Research suggests that CSF ATI ratios could serve as a biomarker for identifying patients with Alzheimer disease at higher risk of ARIA during lecanemab treatment, aiding in safer patient management.:
Source: Neurology Read More
Higher CSF Aß42/Total Tau Ratio Associated With Increased ARIA Risk in Lecanemab
Related Posts
<![CDATA[How Early Environmental Detection Could
Refine Parkinson Disease Risk Models: Rodolfo Savica, MD,
PhD]]>
<![CDATA[How Early Environmental Detection Could Refine Parkinson Disease Risk Models: Rodolfo Savica, MD, PhD]]>
